Perspective Therapeutics, Inc.

AMEX:CATX

Medical - Devices

Healthcare
$0.78 +0.50%

+$0.02 today

Market cap
$94.20M
Beta
1.73
P/E (TTM)
-0.0
EPS (TTM)
-$107.27
52W Low $1.96High $6.16

Volume 2.69M

Average 1.44M

CATX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Perspective Therapeutics, Inc.AMEX: CATX

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was -$1.05M, compared with -$390K a year earlier. Trailing-twelve-month gross profit was -$3.03M.

Context

  • Gross profit amounted to 267.8% of revenue in FY2025, up 209.2 pp from a year earlier.
  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$1.05M or moves back toward the trailing-twelve-month quarterly average of -$756.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.05M-8.5% QoQ
Last fiscal yearDec 2025
-$2.37M-177.8% YoY
LTMMar 2026
-$3.03M-150.0% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-169.2%——
1 year-177.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(2.37M) USD
Year-over-year change
-177.8%

Gross Profit vs competitors

How CATX compares with its peers on the latest reported figures

  • CATX's LTM Mar 2026 gross profit of -$3.03M is the lowest of the 5 companies compared; the peer median is $57.97M.
  • Its year-over-year change of -150.0% is the lowest of 5, against a peer median of +22.2%.
  • Gross profit amounts to 489.8% of revenue for CATX, versus a peer median of 80.1%.
CATX Competitors Peer median
Gross Profit for CATX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NVCRNovoCure LimitedLTM Mar 2026$507.13M +5.7%+4.9%75.2%
DCTHDelcath Systems, Inc.LTM Mar 2026$77.75M +70.1%+230.6%86.0%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$38.18M +38.8%+55.6%85.1%
SRTSSensus Healthcare, Inc.LTM Mar 2026$8.51M -61.6%-26.3%37.7%
CATXPerspective Therapeutics, Inc.LTM Mar 2026-$3.03M -150.0%—489.8%
Peer median (excluding CATX) $57.97M+22.2%+30.2%80.1%

Competitors are the stored peer set for CATX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2022
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.8M7.1M1.43M1.45M884K
Cost of Revenue6.18M5.47M000
Gross Profit4.62M1.63M1.43M(852K)(2.37M)
Gross Margin42.8%23.0%100.0%-58.6%-267.8%
Research & Development2.58M2.6M21.31M41.64M84.22M
Selling, General & Admin9.43M14.21M21.06M26.61M30.23M
Operating Expenses12.01M17.43M42.38M92.34M113.56M
Depreciation & Amortization248K344K981K2.31M3.25M
EBITDA(7.39M)(14.84M)(39.96M)10.46M(100.8M)
EBITDA Margin-68.5%-208.9%-2786.6%719.3%-11402.8%
Operating Income(7.39M)(15.18M)(40.94M)10.46M(113.56M)
Operating Margin-68.5%-213.7%-2855.0%719.3%-12846.6%
Interest Income119K1.12M934K10.52M8.11M
Interest Expense119K084K(48K)376K
Other Income / Expenses119K512K835K(91.84M)9.14M
Income Before Tax(7.27M)(14.67M)(40.11M)(81.38M)(104.43M)
Pre-Tax Margin-67.4%-206.5%-2796.8%-5596.7%-11813.1%
Income Tax Expense(119K)0(2.65M)(2.1M)(793K)
Net Income(7.15M)(14.67M)(46.51M)(79.28M)(103.12M)
Net Margin-66.3%-206.5%-3243.2%-5452.5%-11665.3%
EPS (Basic)(0.13)(0.27)(0.85)(1.23)(1.40)
EPS (Diluted)(0.13)(0.27)(0.85)(1.23)(1.40)
Weighted Avg Shares54.91M54.91M54.91M64.43M73.81M
Weighted Avg Shares (Diluted)54.91M54.91M54.91M64.43M73.81M

Perspective Therapeutics, Inc.

AMEX:CATX

Intrinsic Alpha fair value

Locked

Current Price

$0.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.